Alpha 1-adrenalin receptor antagonist, and preparation and medical use thereof

A receptor antagonist, epinephrine technology, applied in the direction of pharmaceutical formulations, drug combinations, medical preparations containing active ingredients, etc., can solve the problems of not obtaining subtype selectivity prediction ability, not having α1B drugs on the market, etc., and achieving excellent Treatment of benign prostatic hyperplasia, long survival time, good reproducibility

Inactive Publication Date: 2013-02-27
CHINA PHARM UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Numerous structure-activity relationship studies [3,4，5] different α 1B -AR subtype selectivity model, but no model with good predictive ability for subtype selectivity has been obtained, and the α 1B -AR subtype-selective compounds are still relatively small, and there is no α 1B -AR subtype-selective drug launch

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alpha 1-adrenalin receptor antagonist, and preparation and medical use thereof
  • Alpha 1-adrenalin receptor antagonist, and preparation and medical use thereof
  • Alpha 1-adrenalin receptor antagonist, and preparation and medical use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] XBMI: 1-(2,6-Dimethyl-4-bromophenoxy)-2-(3-methoxy-4-hydroxy)propane hydrochloride

[0062] Dissolve 1.5mmol of 4-bromo-2,6-dimethylphenoxyacetone and 1.6mmo of 3-methoxy-4-hydroxyphenethylamine in 5ml of methanol, add a small amount of p-toluenesulfonic acid as a catalyst, and reflux 3h, lowered to room temperature, added 0.2g KBH in batches 4 , so that the temperature of the reaction solution does not exceed 30°C, and react at room temperature for 3h. The methanol was evaporated under reduced pressure, extracted with a small amount of ethyl acetate, the insoluble matter was filtered off, the ethyl acetate was evaporated, the residue was dissolved in absolute ether, and dry HCl gas was introduced. A white solid was obtained, mp 149.8-152.4°C, yield 35%.

[0063] IR (KBr, cm -1 ): 3420, 2926, 1605, 1524, 1279, 1207, 1032.

[0064] 1 HNMR (DMSO-D 6 )δ: 1.43(d, 3H, J=6.47Hz, CH CH 3 ), 2.26(s, 6H, 2×ArCH 3 ), 2.94 (m, 2H, ArCH 2 ), 3.21 (m, 2H, NCH 2 ), 3.63(m,...

Embodiment 2

[0068] XBM Ⅱ: 1-(2,4,6-trimethylphenoxy)-2-(3-methoxy-4-hydroxy)propane hydrochloride

[0069] The reaction conditions were the same as XBMI, and a white solid was obtained, mp 164-166°C, yield 36%.

[0070] IR (KBr, cm -1 ): 3427, 2934, 1610, 1524, 1269, 1217, 1034.

[0071] 1 HNMR (DMSO-D 6 )δ: 1.43 (d, J=6.70Hz, 3H, CH CH 3 ), 2.19 (s, 3H, ArCH 3 ), 2.22(s, 6H, 2×ArCH 3 ), 2.97 (m, 2H, ArCH 2 ), 3.21 (m, 2H, NCH 2 ), 3.63(m, 1H, CHN), 3.73~3.76(2s, 6H, 2×ArOCH 3 ), 3.91 (m, 2H, OCH 2 ), 6.29~6.93(m, 5H, ArH), 9.06(d, 2H, J=37.35Hz, NH 2 + ).

[0072] Molecular formula: C 21 h 29 NO 3 .HCl.

[0073] HRMS: [M+H] + Meas. Mass, 344.22145; Calc. Mass, 344.22202.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
heightaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of pharmaceutical chemistry, in particular to an Alpha1-adrenergic receptor antagonist in the structural formula I, wherein, X represents Br or methyl. The compound of formula I has relatively strong Alpha1-adrenergic receptor antagonistic function and remarkable effect on treating benign prostatic hyperplasia and hypertension. The invention also discloses a preparation method thereof.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to a class of α 1 - Adrenergic receptor antagonist, the invention also discloses its preparation method and medical application. Background technique [0002] alpha 1 - Adrenergic receptors (α 1 -adrenoceptor referred to as α 1 -AR) belongs to the family of guanylate-binding protein (G-protein)-coupled (GPCRs) membrane surface receptors, which triggers signal transduction processes by activating G-proteins after stimulation. alpha 1 - There are multiple subtypes of AR, and it is currently possible to identify α 1 - AR has at least α 1A , α 1B and alpha 1D Three subtypes. three kinds of alpha 1 -AR subtypes have similar structural characteristics, all are single polypeptide chains, each subtype has seven transmembrane domains (TMDs), and the TMDs of the three subtypes have 65%-75% homology. alpha 1 -AR is widely distributed in various tissues and organs, and all three s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07C217/60A61K31/138A61P13/08A61P9/12
Inventor 习保民倪沛洲江振洲王涛
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap